Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107491 | 0.93 | HTR4 (0.37) | HTR7TSHRSMN1; SMN2CHRM3MCHR1 | |
| SCHEMBL4690336 | 0.85 | ADRA1D (0.41) | TSHRMAPK10SMN1; SMN2CHRM3MCHR1 | |
| SCHEMBL4690345 | 0.75 | OPRM1 (0.52) | CHRM3 | |
| SCHEMBL4690214 | 0.74 | PDE10A (0.43) | TSHRMAPK10SMN1; SMN2DRD4 | |
| SCHEMBL4688053 | 0.71 | PDE10A (0.39) | HTR7TSHRMAPK10SMN1; SMN2CYP2D6 | |
| SCHEMBL10847812 | 0.71 | SIGMAR1 (0.59) | HTR7MCHR1DRD4 | |
| SCHEMBL4690106 | 0.69 | PDE10A (0.44) | TSHRMAPK10SMN1; SMN2CYP2D6CYP2C19 | |
| SCHEMBL4691029 | 0.69 | L3MBTL1 (0.35) | HTR7MCHR1L3MBTL1 | |
| SCHEMBL4691461 | 0.68 | MCHR1 (0.38) | HTR7TSHRMAPK10SMN1; SMN2MCHR1 | |
| SCHEMBL4690036 | 0.68 | MCHR1 (0.36) | HTR7TSHRMAPK10SMN1; SMN2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1443046-B1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | KYORIN SEIYAKU KK (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. | 2008-08-14 | — | — | US | disclosed |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1443046-A1 | NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194826-A1 | Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same | CYP4F2, CYP1A2, CYP4B1 | HTR7 1017/4885TSHR 3215/4885MAPK10 2341/4885 |
| US-20050085508-A1 | Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same | OPRM1, OPRD1, HRH4 | HTR7 310/4885TSHR 570/4885MAPK10 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.